pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 28·1 min read
save

J&J offers $5.5 billion settlement to resolve talc lawsuits

Jul 28, 2026·read at Endpoints ↗DealNeutral

Johnson & Johnson has put forward a settlement proposal of $5.5 billion to end the litigation over its talc products.

The proposal follows more than a decade of legal battles and three unsuccessful attempts by the company to use bankruptcy to resolve the claims.

If accepted, the deal would bring finality to the talc saga that has cost the company significant legal expenses and reputational damage.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “J&J proposes $5.5B talc settlement”

read at Endpoints ↗
76 words · retrieved Jul 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
JOHNSON & JOHNSON2
drugs
talc6

related stories

  • Jun 8J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldEndpoints
  • Jun 8STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreSTAT
  • Jun 8STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsSTAT
  • Jun 4Parabilis Medicines charts $413M IPO to back peptide pipelineEndpoints
  • Jun 3Legend surges on early data for ‘in vivo’ lymphoma cell therapyBioPharma Dive